Introduction / objectives
=========================

Bloodstream infections due to *Candida* species play an important complications in severely-ill hospitalized patients which may lead to therapeutic failure. During a 5-year period from 2006-2010, 7 *Candida* species and 14 unidentified strains were identified from 887 candidaemia of patients admitted at Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Methods
=======

*Candida* species were identified according to characteristics of chlamydoconidia production and carbohydrate assimilation/fermentation profile using 13/6 carbon substrates. Only a limited number of *Candida* were tested for antifungal susceptibility by agar gradient diffusion (Etest®)to amphotericin B and fluconazole.

Results
=======

From a total of 887 isolates, *Candida albicans* remains a major pathogen accounted for 50.3%, followed by *C. tropicalis*(27.4%), *C. parapsilosis* (12.5%), *C.guilliermondii* (6%), *C. glabrata* (1.8%), *C. krusei* (0.23%), *C. rugosa* (0.23%), and unidentified species(1.6%). From a total of 103 *C. albicans*, amphotericin B MIC ranged from 0.016-1ug/ml whereas fluconazole MIC ranged were between 0.023 to \> 256ug/ml. Other species tested were *C. tropicalis* (73 strains) which yielded MIC range of 0.19-2ug/ml for amphotericin B and 0.5-\>256 ug/ml for fluconazole. 34 strains of *C. parapsilosis* gave amphotericin B ranged from 0.023-16ug/ml and 0.094-\>256 for fluconazole.

Conclusion
==========

*C. albicans* remains the most prevalence *Candida* species causing candidaemia followed by *C. tropicalis*, *C. parapsilosis* and *C. guilliermondii*. Those non-albicans *Candida* seemed to express decrease susceptibility to both major antifungal agents like amphotericin B and fluconazole whereas a small number of *C. albicans* gave high MIC to fluconazole.
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